Prednisone and vitamin D before chemo for certain lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 study tests whether a short “pre-treatment” with prednisone, with or without vitamin D, can improve outcomes when followed by standard lymphoma chemo. It aims to see if adding vitamin D early can help older adults tolerate or benefit from treatment for specific lymphoma types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 65 or older.
- Your biopsy shows one of these lymphomas: diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3b.
- You have not had any prior treatment for these lymphoma types.
- Your general health is good enough for chemotherapy (performance status 3 or less) and your doctors say you can safely receive an anthracycline-containing plan like R-CHOP or R-miniCHOP.
- Your vitamin D blood level is 40 ng/mL or lower, and you can have the required blood/heart/kidney/liver checks.
- The lymphoma has measurable disease on scan (CT size or PET activity), and you have at least one measurable nodal spot or PET-active spot.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of drugs (called R-mini-MCOP) in people 80 years or older with a type of lymphoma called DLBCL that has not been treated before. The goal is to see if this treatment can help control the lymphoma while being safe for older patients.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This study tests whether adding low-dose radiation to standard chemoimmunotherapy can improve outcomes for people with newly diagnosed large B-cell lymphoma, using a personalized blood test to guide who gets radiation. It may help reduce the risk of the lymphoma returning by targeting sites still showing signs of disease.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.